Consumer Consultation Review Committee
Basic Policy
The purpose of the Consumer Consultation Review Committee is to promote the proper use of ethical drugs, contribute to the realization of patient-participatory medicine, improve the reliability of pharmaceutical companies' pharmaceutical consultation services, and foster drug development through consultations with medical consumers (patients and consumers), medical professionals, and other customers regarding ethical drugs.
In addition, the main activities of the committee are to identify issues related to various problems related to the method and scope of providing information on ethical drugs in the pharmaceutical consultation service, and to study countermeasures and make proposals.
These are the basic policies for FY2026. The following is a list of priority issues and specific activities.
Priority Issues
-
Collect and analyze information related to drug counseling and disseminate it to member companies.
-
Improvement of customer access to pharmaceutical information through the use of digital technology
-
Strengthening of cooperation with organizations related to consultation on pharmaceuticals
Priority Tasks to be addressed
-
To understand and analyze the current status and issues of pharmaceutical consultation, and consider the future functions of pharmaceutical consultation and how it should be done.
-
Promote the use of customer feedback (inquiries, complaints, requests, etc.) received by the Pharmaceuticals Consultation Service.
-
To improve customer accessibility to drug information, utilize new digital technologies, and study methods of content maintenance, system infrastructure construction, and channels (PhindMI, etc.).
-
Deepen cooperation with government, related organizations, and related academic societies, etc., to share information and promote mutual understanding.
-
Consider how information should be provided to patients, etc., and how to improve the scope and accessibility of such information.
-
Identify and improve issues in the provision of information on ethical drugs in compliance with the latest guidelines, etc.
Collaboration with Other Committees
(1) To examine the possibility of collaborating with the Patient Cooperation Committee in providing information to patients.